Octreotide Depot Teva (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Depot Teva, is a somatostatin analog presented as a depot formulation for injectable use. It is used to manage hormone‑secreting tumors and related complications in adults.

GNH USA supplies Octreotide Depot Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide Depot Teva is a long‑acting somatostatin analogue that modulates neuroendocrine activity in several disease states. - Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Neuroendocrine tumors (carcinoid syndrome): alleviates flushing and diarrhea by inhibiting serotonin release. - Thymoma‑associated autoimmune disorders: controls severe hypoglycaemia hypoglycaemic episodes by reducing insulin secretion.

Adverse reactions to Octreotide Depot Teva are reported across a spectrum of frequency.

Common Side Effects: - Abdominal pain - Nausea - Diarrhea - Injection site erythema - Headache - Fatigue

Serious or Rare Side Effects: - Gallbladder sludge or stones - Severe hyperglycaemia or hypoglycaemia - Acute pancreatitis - Cardiac arrhythmias - Anaphylactic reactions - Hepatic dysfunction

When using Octreotide Depot Teva, clinicians should consider several safety measures. - Monitor glucose: patients may develop hyper‑ or hypoglycaia. - Assess gallbladder: periodic ultrasound   gull   g  ",